An energy company has reverted from producing renewable fuels back to conventional production just weeks after filing for ...

Stocks got off to a weak start Thursday as investors confronted data that showed inflation in September came in a bit hotter ...

Making a noteworthy insider sell on October 9, ITEM SECOND IRR TRUST FBO JACOB J WESTPHAL ua of JEFFREY R WESTPHAL dated October , 10% Owner at Vertex VERX, is reported in the latest SEC filing.

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price ...

Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

Vertex Energy Inc (VTNR) stock saw a decline, ending the day at $0.11 which represents a decrease of $-0.01 or -8.33% from the prior close of $0.12. The stock opened at $0.11 and touched a low of $0.1 ...

Vertex’s core cystic fibrosis portfolio remains its top/bottom-line driver, with elongated patent expiry for TRIKAFTA/KAFTRIO ...

October 9: Sold 48,957 shares at an average price of $41.31. After these sales, the trust retains ownership of approximately ...

With an FDA decision looming over its first foray into the acute pain space, Vertex Pharmaceuticals has commissioned a pair ...

Adirondack Trust Co. lowered its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by ...

What Happened: Westphal's decision to sell 1,225,000 shares of Vertex was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Monday. The total value of the sale is $48,289 ...

In a recent transaction, Jeffrey Westphal, a significant shareholder of Vertex (NASDAQ:VRTX), Inc. (NASDAQ:VERX), sold 1,225,000 shares of the company's Class A common stock. The sale, completed on ...